How EMPAVELI can help | LDH NORMALIZATION
The majority of people taking EMPAVELI reduced their LDH levels to within the normal range (113-226 U/L). This information is for observation only and no conclusions can be made on the effect of EMPAVELI on LDH normalization. No comparisons can be made between those taking EMPAVELI and those taking eculizumab in PEGASUS or those in the control arm (excluding complement inhibitors) in PRINCE. LDH normalization in people with and without previous complement inhibitor treatment
Nearly 2/3 of people taking EMPAVELI reduced their LDH levels to within the normal range (113-226 U/L).
Jillian is an adult with PNH who's taken EMPAVELI.
In people who had never received a complement inhibitor (PRINCE)
In people who had previously received a C5i (PEGASUS)
At Week 26 in PRINCE
80
At Week 16 in PEGASUS
80
70
70
60
66%
71%
of people taking EMPAVELI achieved LDH normalization
of people taking EMPAVELI achieved LDH normalization
60
50
50
40
40
30
30
20
20
10
0%
15%
10
0
Control arm (excluding complement inhibitors) n=18
EMPAVELI n=35
0
EMPAVELI n=41
eculizumab n=39
These data include only people who did not require a transfusion during the study.
These data include only people who did not require a transfusion during the study.
Long-term Hb and LDH data
see additional data
IMPORTANT SAFETY INFORMATION What is the most important information I should know about EMPAVELI? EMPAVELI is a medicine that affects your immune system and may lower the ability of your immune system to fight infections.
C5i=C5 inhibitor; Hb=hemoglobin; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria.
Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide.
24
25
Made with FlippingBook - professional solution for displaying marketing and sales documents online